Health care professionals who treat patients with cold agglutinin disease, a rare autoimmune hemolytic anemia, comment on symptoms that make the condition difficult to diagnose and remark on the ...

Jeremy Lorber, MD, explains what is known about the pathophysiology of a rare autoimmune hemolytic anemia, cold agglutinin disease. Neil Minkoff, MD: Hello, and welcome to this AJMC® Peer Exchange ...

SEVERAL observers 1–4 have reported cases of acute anemia occurring in patients with primary atypical pneumonia who have developed high titers of cold agglutinins (autohemagglutinins). Since all these ...

Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia — a condition in which you have inadequate red blood cells due to premature destruction of those cells by your own immune ...

In a recent case report published in the Journal of Clinical Laboratory Analysis, researchers presented two cases to highlight the impact of cold agglutinin syndrome (CAS) on clinical presentations in ...

Imagine not being able to stay outdoors during winter. Or having to put on gloves to open the fridge. New knowledge and better treatment give hope to people who suffer from a rare cold disease. For ...

Anemia caused by the autoimmune disorder cold agglutin disease now has its first approved treatment, a Sanofi drug designed to block a pathway key to the progression of this condition. The FDA’s ...

What are the symptoms for cold agglutinin disease, and how is it diagnosed? -- P.W. ANSWER: Cold agglutinin disease is a specific type of anemia where antibodies attack and destroy a person’s own red ...

Patients with the rare blood disorder cold agglutinin disease (CAD), now have a drug that will help limit the blood transfusions they need. On Friday, the FDA approved Sanofi’s Enjaymo (sutimlimab) ...

(RTTNews) - Sanofi (SNYNF, SNY) said that the U.S. Food and Drug Administration has approved Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults ...

Please provide your email address to receive an email when new articles are posted on . Research presented at ASH Annual Meeting and Exposition provided an exciting update on many of the ...

Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 billion. A ...